The Reproductive Medicine Center of NanHua Affiliated Hospital shares clinical research findings

Hunan Daily · New Hunan Client May 15th News (Correspondent Chen Yongzhe): Recently, the "10th National Conference on Colposcopy and Cervical Pathology" organized by the Chinese Society of Colposcopy and Cervical Pathology (CSCCP), the Cervical Cancer Prevention and Control Research Professional Committee of the Chinese Maternal and Child Health Association, and sponsored by the "Chinese Journal of Obstetrics and Gynecology" was held at the Social Mountain International Conference Center in Tianjin. The theme of this conference was "Promoting Integration of Medical Treatment and Prevention of Cervical Cancer", bringing together renowned experts from home and abroad to discuss cutting-edge issues in the female reproductive tract. With more than 1200 attendees on-site and over 13,000 online viewers, this conference has become an important event in the field of colposcopy and cervical pathology worldwide.

Professor Dong Weilei from the Reproductive Medicine Center of the First Affiliated Hospital of South China University leads a clinical research team dedicated to fertility preservation and precise diagnosis and treatment of cervical cancer. At the CSCCP conference, their team representative, Yu Furong, shared original research on the scientific translation and practice of cervical cancer accumulated over the years. Yu Furong delivered a keynote speech titled "Evaluation of the Application Efficacy of Female DNA Methylation Testing in Vaginal Self-collected Specimens," which received appreciation from experts and peers present at the conference.

Cervical cancer, as a preventable malignant tumor, poses a high risk for most unscreened women. To accelerate the elimination of cervical cancer, the World Health Organization proposed interim targets for 2030: "90% of girls complete HPV vaccination before age 15, 70% of women aged 35-45 undergo high-quality screening, and 90% of diagnosed patients receive treatment." Currently, China's cervical cancer screening situation still lags behind WHO's targets, with a screening rate of only 43.4% among women aged 35-44. Research has found that the main reasons for the low screening rate are high hospital visitation time and economic costs, as well as uneven distribution of medical resources. To address this issue, the team conducted PAX1/JAM3 methylation testing on self-collected cervical samples. This method is simple, repeatable, and accurate, overcoming the limitations of time and space in cervical cancer screening for women. It also helps reduce the risk of missed detection of occult lesions in postmenopausal women due to declining hormone levels.

The Reproductive Medicine Center of the hospital has been deeply involved in clinical practice in the field of gynecological cancer for many years, committed to providing high-level treatment for gynecological cancer patients and improving their survival rates and quality of life. Additionally, the center focuses on scientific exploration and research summaries of clinical findings and patterns in gynecological tumor treatment. The speech delivered by NanHua Affiliated Hospital at the CSCCP conference not only showcased the correct direction of clinical translational research at the Reproductive Medicine Center but also demonstrated the team's dedication to beneficial clinical and basic scientific research, earning recognition from experts both domestically and internationally.